Hutchin Hill Capital’s Aratana Therapeutics, Inc. PETX Stock Holding History

Hutchin Hill Capital’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-21,300	Closed	-$131K	–	813
2017 Q3	$131K	Buy	+21,300	New	+$135K	0.01%	709
2016 Q4	–	Sell	-131,000	Closed	-$1.23M	–	899
2016 Q3	$1.23M	Buy	+131,000	New	+$1.09M	0.03%	346
2015 Q4	–	Sell	-75,000	Closed	-$635K	–	810
2015 Q3	$635K	Sell	75,000 -176,900	-70%	-$2.99M	0.02%	466
2015 Q2	$3.81M	Buy	251,900 +600	+0.2%	+$8.66K	0.1%	192
2015 Q1	$4.02M	Buy	251,300 +1,300	+0.5%	+$23.1K	0.11%	202
2014 Q4	$4.46M	Buy	250,000 +62,500	+33%	+$779K	0.16%	104
2014 Q3	$1.88M	Buy	187,500 +13,412	+8%	+$163K	0.07%	251
2014 Q2	$2.72M	Buy	174,088 +24,088	+16%	+$341K	0.12%	110
2014 Q1	$2.78M	Buy	150,000 +37,500	+33%	+$751K	0.14%	106
2013 Q4	$1.9M	Sell	112,500 -2,500	-2%	-$50.8K	0.13%	155
2013 Q3	$1.88M	Sell	115,000 -60,000	-34%	-$631K	0.17%	107
2013 Q2	$1.32M	Buy	+175,000	New	+$1.38M	0.14%	98

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Hutchin Hill Capital's PETX Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2017, closing a stake of 21,300 shares — an estimated $131K sold.

Hutchin Hill Capital first reported a position in PETX in Q2 2013 and held it in 12 quarters. The position peaked at $4.46M in Q4 2014. 105 funds tracked by Wall St. Rank hold PETX as of Q4 2017.

Hutchin Hill Capital reported no remaining Aratana Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Hutchin Hill Capital sold 21,300 Aratana Therapeutics, Inc. shares in Q4 2017, an estimated $131K.
Hutchin Hill Capital first reported a position in Aratana Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
Hutchin Hill Capital's Aratana Therapeutics, Inc. position peaked at $4.46M in Q4 2014.
105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.